Y, and significant rates of AUR Lapatinib Tykerb was low at M Nnern with tolterodine ER treated with or without a blocker, independently Ngig of the H Height of the PSA or the size E of the prostate. In oxybutynin, propiverine, and solifenacin trials, there was little evidence of the safety problems at M Nnern whether these agents as monotherapy or have been used ablocker. The resultsAlthough a variety of agents as m Possible treatments for overactive bladder have been examined are anticholinergics remain the drug of choice. This analysis was therefore in favor of the agents administered systemically forwhich muscarinic receptor antagonism of the most important mechanism of action is. Targeted agents have been ben CONFIRMS, in order to obtain approval for Food and Drug Administration and are prescribed together inOAB use in the United States, the means to fulfill these requirements darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine and trospium. Research literature for articles, VER between 1966 and December 2009 were published using Medline and the Cochrane database of rtern Schlüsselw: nticholinergic, carpet lacebocontrolled study.These studies were ends with OBJECTS, Which were combined using medical subject heading bladder veractive. In addition, all relevant information in the bibliographies of retrieved articles cited. We also have relevant data records Tze with data on reported rates of gastrointestinal side effects of anticholinergic drugs for OAB from the U.S. FDA website identified. The anf Ngliche search was conducted by two examiners and was upgraded from a third party. Each study was then independently evaluated ngig eligible for inclusion / exclusion criteria assigned by pairs of authors, with t evaluates the quality of each manuscript using a modified Jadad scoring scheme, the following parameters: The method and level of concealment, randomization, blinding , dealing with interruptions, the relevance of the statistical tests, the criteria for inclusion and exclusion, and methods of evaluation of side effects. The walls OBJECTS Were in electronic form, designed for keywords purchased and labeled using the software Features to facilitate the abstraction of the data. Each paper was then checked manually by the authors that associates evaluated the results of safety for each adult TSST hnung constipation or gastrointestinal side effects with intestinal motility Disturbances. Reader summary information about the following areas shared with a spreadsheet program: participant characteristics, drug and dose, duration of observation, the criteria of quality t Jadad assessment, reporting the number of patients suffering from constipation in each group, and the total number of participants in each group. Criteria for inclusion and exclusion of the analysis considers only written reports in English and excluded studies are not withOAB in patients who were no relevant side effects or had carried out had no extractable data that were not controlled Placebo-strip in which the duration of treatment was less than 14 days, or copies of the analysis were summarized from publications have been captured already in the retrieval. The analysis of statistical data were summarized as odds ratios and both the use of Mantel Haenszel fixed effects and coincidence Lligen effects model combined DerSimonian.